Clinical Trials Logo

CUP clinical trials

View clinical trials related to CUP.

Filter by:
  • None
  • Page 1

NCT ID: NCT03385980 Completed - NSCLC Stage IV Clinical Trials

Donation of Post Mortem Tumor Tissues

DONUM
Start date: February 11, 2016
Phase:
Study type: Observational

DONUM is an observational prospective independent protocol for patients with advanced lung cancer, colorectal cancer or cancer of unknown primary, willing to donate their tumor tissue samples post mortem for biomedical research purposes. All patients who fulfill the inclusion criteria will be eligible for the study after giving their Informed consent. Informed Consent will be obtained in two steps. During the pre-information step patients will be acquainted with the existence of a post-mortem cancer tissue donation research program governed by the DONUM protocol. If the patients manifest interest to participate into the program (in writing) during the pre-information step, they will proceed to step 2 and undergo the final informed consent process.

NCT ID: NCT03210298 Recruiting - Colorectal Cancer Clinical Trials

International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)

PIPACRegis
Start date: January 2016
Phase:
Study type: Observational [Patient Registry]

Multicentric, international, web-based prospective documentation of the indications and results of Pressurized Aerosol Chemotherapy (so-called PIPAC or PITAC) for treating malignant pleural and peritoneal diseases. Indication is decided by the treating physician. There are no predefined inclusion or exclusion criteria.

NCT ID: NCT02628379 Completed - Metastatic Disease Clinical Trials

Outcomes of FoundationOne Directed Therapy in Cancer of Unknown Primary

Start date: May 2015
Phase:
Study type: Observational

The goal of the current study is to determine whether Foundation Medicine's next generation sequencing assay, called FoundationOne, will provide information that allows physicians to make treatment decisions using targeted therapies in clinical trials or FDA approved therapies, including "off-label" agents, that result in superior OS compared to historical outcomes for standard CUP therapy.